Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9

Microbiome composition can impact disease courses and also immunotherapy outcomes in solid tumours. It is still unclear how the microbiome might impact treatments in oncology, but also how modulation via antibiotics might interfere. Elegant work now identified interleukin-9 and dysbiosis as relevant...

Descripción completa

Detalles Bibliográficos
Autor principal: Halama, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652919/
https://www.ncbi.nlm.nih.gov/pubmed/32843683
http://dx.doi.org/10.1038/s41416-020-01030-0
_version_ 1783607795788021760
author Halama, Niels
author_facet Halama, Niels
author_sort Halama, Niels
collection PubMed
description Microbiome composition can impact disease courses and also immunotherapy outcomes in solid tumours. It is still unclear how the microbiome might impact treatments in oncology, but also how modulation via antibiotics might interfere. Elegant work now identified interleukin-9 and dysbiosis as relevant factors, providing some answers for these questions.
format Online
Article
Text
id pubmed-7652919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76529192021-08-26 Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9 Halama, Niels Br J Cancer Editorial Microbiome composition can impact disease courses and also immunotherapy outcomes in solid tumours. It is still unclear how the microbiome might impact treatments in oncology, but also how modulation via antibiotics might interfere. Elegant work now identified interleukin-9 and dysbiosis as relevant factors, providing some answers for these questions. Nature Publishing Group UK 2020-08-26 2020-11-10 /pmc/articles/PMC7652919/ /pubmed/32843683 http://dx.doi.org/10.1038/s41416-020-01030-0 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Halama, Niels
Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title_full Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title_fullStr Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title_full_unstemmed Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title_short Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
title_sort bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652919/
https://www.ncbi.nlm.nih.gov/pubmed/32843683
http://dx.doi.org/10.1038/s41416-020-01030-0
work_keys_str_mv AT halamaniels bowelinflammationincancerpatientsthemicrobiomeantibioticsandinterleukin9

Ejemplares similares